Last reviewed 2026-05-31 · How we verify

MenACWY-TT

MenACWY-TT is a Meningococcal conjugate vaccine Biologic drug developed by Pfizer. It is currently FDA-approved for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 months of age and older. Also known as: Nimenrix.

MenACWY-TT is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by linking polysaccharide antigens to tetanus toxoid carrier protein.

MenACWY-TT is a conjugate vaccine used to prevent meningitis and other infections caused by the meningococcal bacteria. It is a small molecule vaccine, classified as a conjugate vaccine, which is used to stimulate an immune response against the meningococcal bacteria.

At a glance

Mechanism of action

The vaccine contains purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y, each conjugated to tetanus toxoid (TT) as a carrier protein. This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, resulting in stronger and more durable antibody production compared to unconjugated polysaccharide vaccines. The induced antibodies provide protection against invasive meningococcal disease caused by these four serogroups.

Approved indications

• Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 months of age and older

Common side effects

• Injection site pain
• Injection site erythema
• Injection site swelling
• Myalgia
• Fatigue
• Headache
• Fever

Key clinical trials

• MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults (PHASE4)
• A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants (PHASE2)
• Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine (PHASE3)
• Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age (PHASE3)
• Adolescent MenACWY Booster Study (PHASE4)
• Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine (PHASE3)
• A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered). (PHASE3)
• Comparison of Two Meningococcal ACWY Conjugate Vaccines (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MenACWY-TT CI brief — competitive landscape report
• MenACWY-TT updates RSS · CI watch RSS
• Pfizer portfolio CI

Frequently asked questions about MenACWY-TT

Related

• Drug class: All Meningococcal conjugate vaccine drugs
• Manufacturer: Pfizer — full pipeline
• Therapeutic area: All drugs in Immunology / Infectious Disease
• Indication: Drugs for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 months of age and older
• Also known as: Nimenrix

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing